Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buprenorphine (Indivior)
- Development stage
- Approved
- Lead developer
- Indivior
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Extended-release buprenorphine is a long-acting injectable formulation of the partial mu-opioid agonist buprenorphine, specifically developed for the treatment of moderate-to-severe opioid use disorder (OUD). Administered subcutaneously, typically on a monthly or weekly basis, the medication forms a depot that releases buprenorphine at a controlled rate to maintain steady-state therapeutic plasma levels. This formulation is designed to suppress opioid withdrawal symptoms and cravings while significantly reducing the risk of medication diversion and improving treatment adherence compared to daily transmucosal products. NYU Langone Health is evaluating the clinical utility of this formulation within the carceral system through the SO-BUP trial, which compares the effectiveness of initiating treatment at the time of jail admission versus shortly before release to optimize post-release outcomes and reduce overdose risk.
- Brand names
- SublocadeBrixadiBuvidal
- Other names
- extended-release buprenorphineXR-BXR-Bupbuprenorphine depotbuprenorphine extended-release
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NOP (Nociceptin/orphanin FQ peptide receptor)
Beyond the preview
Go deeper on buprenorphine (Indivior).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buprenorphine (Indivior).